By Ben Butkus

Smiths Detection said today that its diagnostics business has signed a collaboration and license agreement with Novartis Diagnostics to develop diagnostic tests based on Smiths' clinical diagnostics system and linear-after-the-exponential, or LATE, PCR technology.

Together, Smiths and Novartis plan to develop and market highly multiplexed assays for a variety of infectious diseases, beginning with a focus on healthcare-associated infections, officials from the companies said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.